The druggable genome

被引：2401

作者：

Hopkins, AL ^{[1
]}

Groom, CR ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Mol Informat Struct & Design Dept, Sandwich CT13 9NJ, Kent, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 09期

关键词：

D O I：

10.1038/nrd892

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.

引用

页码：727 / 730

页数：4

共 15 条

[1] The InterPro database, an integrated documentation resource for protein families, domains and functional sites [J].

Apweiler, R ;

Attwood, TK ;

Bairoch, A ;

Bateman, A ;

Birney, E ;

Biswas, M ;

Bucher, P ;

Cerutti, T ;

Corpet, F ;

Croning, MDR ;

Durbin, R ;

Falquet, L ;

Fleischmann, W ;

Gouzy, J ;

Hermjakob, H ;

Hulo, N ;

Jonassen, I ;

Kahn, D ;

Kanapin, A ;

Karavidopoulou, Y ;

Lopez, R ;

Marx, B ;

Mulder, NJ ;

Oinn, TM ;

Pagni, M ;

Servant, F ;

Sigrist, CJA ;

Zdobnov, EM .

NUCLEIC ACIDS RESEARCH, 2001, 29 (01) :37-40

[2] The end of the beginning for genomic medicine [J].

Bailey, D ;

Zanders, E ;

Dean, P .

NATURE BIOTECHNOLOGY, 2001, 19 (03) :207-209

[3] Gene number - What if there are only 30,000 human genes? [J].

Claverie, JM .

SCIENCE, 2001, 291 (5507) :1255-1257

[4] Drug discovery: A historical perspective [J].

Drews, J .

SCIENCE, 2000, 287 (5460) :1960-1964

[5] The role of innovation in drug development [J].

Drews, J ;

Ryser, S .

NATURE BIOTECHNOLOGY, 1997, 15 (13) :1318-1319

[6] Genomic sciences and the medicine of tomorrow [J].

Drews, J .

NATURE BIOTECHNOLOGY, 1996, 14 (11) :1516-&

[7] Metabolite profiling for plant functional genomics [J].

Fiehn, O ;

Kopka, J ;

Dörmann, P ;

Altmann, T ;

Trethewey, RN ;

Willmitzer, L .

NATURE BIOTECHNOLOGY, 2000, 18 (11) :1157-1161

[8] Initial sequencing and analysis of the human genome [J].

Lander, ES ;

Int Human Genome Sequencing Consortium ;

Linton, LM ;

Birren, B ;

Nusbaum, C ;

Zody, MC ;

Baldwin, J ;

Devon, K ;

Dewar, K ;

Doyle, M ;

FitzHugh, W ;

Funke, R ;

Gage, D ;

Harris, K ;

Heaford, A ;

Howland, J ;

Kann, L ;

Lehoczky, J ;

LeVine, R ;

McEwan, P ;

McKernan, K ;

Meldrim, J ;

Mesirov, JP ;

Miranda, C ;

Morris, W ;

Naylor, J ;

Raymond, C ;

Rosetti, M ;

Santos, R ;

Sheridan, A ;

Sougnez, C ;

Stange-Thomann, N ;

Stojanovic, N ;

Subramanian, A ;

Wyman, D ;

Rogers, J ;

Sulston, J ;

Ainscough, R ;

Beck, S ;

Bentley, D ;

Burton, J ;

Clee, C ;

Carter, N ;

Coulson, A ;

Deadman, R ;

Deloukas, P ;

Dunham, A ;

Dunham, I ;

Durbin, R ;

French, L .

NATURE, 2001, 409 (6822) :860-921

[9]

*LEHM BROTH, 2001, FRUITS GENOMICS

[10] Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].

Lipinski, CA ;

Lombardo, F ;

Dominy, BW ;

Feeney, PJ .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25

← 1 2 →